{"id":52958,"date":"2026-01-13T19:46:41","date_gmt":"2026-01-13T18:46:41","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/01\/13\/taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach\/"},"modified":"2026-01-13T19:46:41","modified_gmt":"2026-01-13T18:46:41","slug":"taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/01\/13\/taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach\/","title":{"rendered":"Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Jan 13:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1344. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein-targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show that it can remodel the tumor microenvironment and enhance antitumor immunity by depleting fibroblast activation protein-positive cancer-associated fibroblasts and activating multiple immune cell types. In mouse lung tumor and human organoid models, MiNK-215 promotes durable, antigen-specific T-cell responses and overcomes resistance to immunotherapy without causing off-target toxicity. See related article by Chantzoura et al., p. XX .<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41528110\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260113134640&amp;v=2.18.0.post22+67771e2\">41528110<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1344\">10.1158\/2326-6066.CIR-25-1344<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Jan 13:OF1-OF2. doi: 10.1158\/2326-6066.CIR-25-1344. Online ahead of print. ABSTRACT Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein-targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show &#8230; <a title=\"Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/01\/13\/taking-multiple-shots-on-goal-with-an-armed-invariant-nk-cell-approach\/\" aria-label=\"Read more about Taking &#8220;Multiple Shots on Goal&#8221; with an Armed Invariant NK Cell Approach\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-52958","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/52958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=52958"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/52958\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=52958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=52958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=52958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}